ARAY ACCURAY INC
FY2025 10-K
ACCURAY INC (ARAY) filed its fiscal year 2025 10-K annual report with the SEC on Aug 28, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and sale of advanced radiation therapy systems including CyberKnife robotic radiosurgery and TomoTherapy helical radiation platforms
- • New product emphasis: Introduction of Accuray Helix CT-guided helical radiotherapy system combining affordability and automation to expand radiation access
Management Discussion & Analysis
- • Revenue impact negative from U.S. reduced budgets and longer installations, continuing through FY2026, no specific revenue $ reported
- • Gross margin and net income adversely affected by inflation, supply chain, freight costs; impact expected through at least calendar year 2025, no margin % given
Risk Factors
- • Regulatory risk from FDA and other clearances, critical for product sales and R&D costs impacting future capital needs
- • Macroeconomic exposure to China anti-corruption campaign and stimulus timing, affecting operations and liquidity forecasts
Financial SummaryXBRL
Revenue
$459M
Net Income
-$2M
Gross Margin
32.1%
Operating Margin
1.7%
Net Margin
-0.3%
ROE
-2.0%
Total Assets
$470M
EPS (Diluted)
$-0.02
Operating Cash Flow
$3M
Source: XBRL data from ACCURAY INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACCURAY INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.